Increased morbidity associated with chronic infection by an epidemic *Pseudomonas aeruginosa* strain in CF patients

M Al-Aloul, J Crawley, C Winstanley, C A Hart, M J Ledson, M J Walshaw

**Background:** Chronic pulmonary infection with transmissible *Pseudomonas aeruginosa* strains in individuals with cystic fibrosis (CF) has been reported, raising issues of cross infection and patient segregation. The first such strain to be described (the Liverpool epidemic strain, LES) is now widespread in many UK CF centres. However, whether such infection carries a worse prognosis is unknown. To address this, the clinical course of a group of CF patients chronically infected by LES was compared with that in patients harbouring unique strains.

**Methods:** Using *P aeruginosa* strain genotyping, two cohorts of CF patients attending the Liverpool CF service were identified who were LES positive or negative in 1998 and remained so until 2002. From these, two groups of 12 patients were matched in 1998 for age, spirometric parameters, and nutritional state and their clinical course was followed for 5 years. Patients chronically infected with *Burkholderia cepacia* were excluded.

**Results:** Patients chronically infected with LES had a greater annual loss of lung function than those not chronically infected by LES (mean difference between groups –4.4% (95% CI –8.1 to –0.9; p<0.02)), and by 2002 their percentage predicted forced expiratory volume in 1 second (FEV1) was worse (mean 65.0% v 82.6%, p<0.03). Their nutritional state also deteriorated over the study period (mean difference between groups in body mass index –0.7 (95% CI –1.2 to –0.2; p<0.01)), such that by 2002 they were malnourished compared with LES negative patients (mean BMI 19.4 v 22.7, p<0.02).

**Conclusions:** Chronic infection with the Liverpool epidemic *P aeruginosa* strain in CF patients confers a worse prognosis than infection with unique strains alone, confirming the need for patient segregation. Since this strain is common in many CF units, strain identification in all CF centres is essential. This can only be carried out using genomic typing methods.
The mean difference between groups in the annual rate of change of FEV$_1$ was $-4.4\%$ (95% CI $-8.1$ to $-0.9; p<0.02$), such that by 2002 LES positive patients had a worse FEV$_1$ % predicted (mean (SD) 65.0 (18.6)% v 82.6 (20.3)%; $p<0.03$).

Furthermore, their nutritional state deteriorated over the study period (mean (SD) rate of change of BMI per year $-0.3$ (0.6) v +0.3 (0.63); $p<0.01$), such that by the end of the study they were significantly malnourished compared with LES negative patients (mean (SD) BMI 19.4 (2.3) kg/m$^2$ v 22.7 (3.5) kg/m$^2$; $p<0.02$). Although the number of outpatient clinic attendances and respiratory exacerbations requiring oral or intravenous antibiotics did not differ between the two groups (table 2), there was a trend to an increased need for hospital admissions ($p=0.07$) and days of intravenous antibiotic use ($p=0.09$) in the LES group.

More LES positive patients were started on azithromycin for its immune modulatory effect (5/12 v 0/12; $p<0.05$) during the 5 year period. No patient had any episodes of ABPA or pneumothorax during the 5 year study period or any major interventions (such as PEG or Portacath insertion).

**DISCUSSION**

Highly transmissible (epidemic) strains of *P aeruginosa* have recently been shown to chronically infect patients with CF.$^1$-$^5$ The first of these was described in our local paediatric centre in 1996,$^1$ and this LES has now spread to most CF centres in the UK,$^2$ prompting calls for patient segregation. However, whether cross infection with these transmissible, often multiresistant, strains contributes to excess morbidity and mortality in CF patients was previously unknown.$^1$ While one study suggested that patients chronically infected by a different (less prevalent) epidemic strain underwent more inpatient treatment over 1 year,$^2$ it was unclear whether these patients acquired the epidemic strain because they were more severely affected by CF and therefore spent more time in hospital, and not vice versa. Furthermore, this study showed no deterioration in objective parameters of the clinical condition.

For the first time we have clearly shown that a group of CF patients chronically infected by a major *P aeruginosa* epidemic strain had a greater deterioration in pulmonary function and nutritional status than matched patients over a prolonged time period. Furthermore, there was a trend to an increased treatment burden in these patients. This is important since this transmissible strain tends to be multiresistant, defined as resistant to all antibiotics in two or more classes of antipseudomonal antibiotics$^2$ (as found in 11 of the 12 patients in this study), and we have already shown that the repeated use of the limited range of nephrotoxic antibiotics to which the strain is sensitive has caused renal damage in our adult CF patients.$^8$

This study provides compelling evidence that chronic infection by LES is a serious risk factor for CF patients, especially since it is capable of cross infecting patients already harbouring unique strains (superinfection).$^6$ However, current segregation policies suggest that all patients chronically infected by *P aeruginosa* should be separated from the remainder.$^1$ Such policies are illogical in that they assume patients infected by unique strains are a risk to the remainder which, by definition, is not possible,$^1$ and they also ignore the risk of superinfection by epidemic strains. Furthermore, cohorting all *P aeruginosa* infected patients together will enhance the contact density, thereby increasing the risk of superinfection. Unfortunately, epidemic strains can only be identified by genomic techniques since antibiogram and morphotype methods are indistinguishable.$^6$-$^8$ In keeping with this, we regularly genotype all *P aeruginosa* isolates in our unit in order to diminish the risk of cross infection. A rapid
technique for typing LES directly from sputum has already been described.15 Now that LES is common in many other CF units throughout the UK, we advise other CF units to adopt the same procedure.

Authors’ affiliations
M Al-Aloul, J Crawley, M J Ledson, M J Walshaw, Regional Adult Cystic Fibrosis Unit, The Cardiothoracic Centre, Liverpool, UK
C Winstanley, C A Hart, Department of Medical Microbiology, Liverpool University, Liverpool, UK
This was an unfunded study.

Conflict of interest: none of the authors has declared any conflict of interest.

MA collected and analysed the data and wrote the first draft of the paper. JC collected data on antibiotic use and researched central home care records. CW and CAH performed the genomic typing of Pseudomonas isolates and provided input into writing the manuscript. MJW contributed ideas to study design and helped write the manuscript. MJW contributed ideas to study design, drafted the manuscript, and supervised the study.

REFERENCES
12 Ogienyi B, Peterson US, Holby N. Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients. APNUS 1993;101:168–73.

LUNG ALERT

Ambroxol and reduction of COPD exacerbations

This prospective, randomised, double blind, multicentre, placebo controlled study examined the effect of ambroxol (an agent stimulating mucociliary clearance and surfactant production) in preventing acute exacerbations of COPD. 242 patients with GOLD stage IIa COPD, a history of chronic bronchitis, abnormal chest auscultation, and at least one exacerbation in the previous year were recruited and randomised to receive ambroxol or placebo for 12 months. An exacerbation was defined as the presence of purulent sputum with at least one of the following: temperature >38°C, general malaise, dyspnoea, difficult expectoration, or new systemic leucocytosis. There was no significant difference in the primary end point—the number of exacerbations—between the ambroxol and placebo groups at either 6 or 12 months (63% v 60% at 6 months, 56% v 53% at 12 months, respectively).

Systematic reviews have suggested a significant reduction in the number of exacerbations in patients with mild COPD and chronic bronchitis treated with mucolytic agents. These reviews included many studies using N-acetylcysteine. The AMETHIST trial shows the importance of examining the evidence for individual mucolytic drugs before prescription.

W R Perera
Clinical Research Fellow, St Bartholomew’s Hospital, London, UK;
Wayomiperera@aol.com

Table 2 Treatment burden of study patients

<table>
<thead>
<tr>
<th></th>
<th>Epidemic strain (n = 12)</th>
<th>Unique strains (n = 12)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital admissions</td>
<td>1.6 (1.4; 0.2–4.4)</td>
<td>0.7 (0.5; 0.0–1.6)</td>
<td>0.07</td>
</tr>
<tr>
<td>Outpatient clinic visits</td>
<td>6.3 (1.3; 3.8–8.0)</td>
<td>6.1 (1.4; 4.0–9.4)</td>
<td>0.51</td>
</tr>
<tr>
<td>Pulmonary exacerbations requiring oral or IV antibiotics</td>
<td>4.1 (1.9; 1.8–7.8)</td>
<td>3.1 (1.0; 1.4–4.6)</td>
<td>0.24</td>
</tr>
<tr>
<td>Total IV antibiotic days</td>
<td>39.0 (26.5; 4.4–150.8)</td>
<td>23.1 (13.2; 0.0–42.2)</td>
<td>0.09</td>
</tr>
</tbody>
</table>

Data are presented as mean (SD; range).

12 Ogienyi B, Peterson US, Holby N. Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients. APNUS 1993;101:168–73.
Increased morbidity associated with chronic infection by an epidemic \textit{Pseudomonas aeruginosa} strain in CF patients

M Al-Aloul, J Crawley, C Winstanley, C A Hart, M J Ledson and M J Walshaw

\textit{Thorax} 2004 59: 334-336
doi: 10.1136/thx.2003.014258